Larry Spitcaufsky

Larry Spitcaufsky is a declared insider of Sonnet BioTherapeutics Holdings, Inc., with filings sourced from SEC (Form 4). Between 13 December 2017 and 12 April 2019, the trades on record add up to 34 filings.

In open-market terms, that means 8 purchases worth €15k on one side and 18 sales worth €46k on the other. The net balance comes to €30k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 5 share grants. So far in 2019, the count stands at 1 purchase and no sales.

In size, the median ticket on the buying side is €2,088. 8 out of 8 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The latest filing, published on 23 May 2019, reports an open-market purchase of €2,071 in Sonnet BioTherapeutics Holdings, Inc. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.